News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Boehringer Ingelheim Corporation Release: First Patient Enrolled in New Cardiovascular and Renal Outcomes Trial for linagliptin in Type 2 Diabetes



7/31/2013 9:46:28 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim (BI) and Eli Lilly and Company today announced enrollment of the first patient into a cardiovascular and renal outcomes trial for linagliptin (Trajenta®). The CARMELINA1 (CArdiovascular safety and Renal Microvascular outcomE with LINAgliptin in patients with Type 2 Diabetes mellitus at high vascular risk) trial will investigate the once daily dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, on cardiovascular and renal microvascular outcomes in adults with Type 2 Diabetes at risk of cardiovascular and renal events.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES